Brief: Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response In Covid-19 Patients
25/08/2021 14:38
Aug 25 (Reuters) - Noxopharm Ltd NOX.AX :
* NOXOPHARM PHASE I CLINICAL TRIAL SHOWS ANTI-INFLAMMATORY
RESPONSE IN COVID-19 PATIENTS
* NOXOPHARM - STARTED DISCUSSIONS TO ADD VEYONDA TO ONE OF
GLOBAL
CLINICAL TRIAL PROGRAMS TO IDENTIFY EFFECTIVE ANTI-INFLAMMATORY
THERAPIES IN COVID-19
Source text for Eikon: ID:nBw6r0B7a
Further company coverage: NOX.AX
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Noxopharm
See all newsAustralia's Noxopharm hits three-month low on discounted placement
Brief: Noxopharm Receives Commitments For Placement
Brief: Noxopharm Requests Trading Halt Pending Material Capital Raising Announcement
Brief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential